Analyst Price Target is $21.50
▲ +1.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $21.50, with a high forecast of $23.00 and a low forecast of $20.00. The average price target represents a 1.03% upside from the last price of $21.28.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Amphastar Pharmaceuticals. This rating has held steady since May 2021, when it changed from a Hold consensus rating.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.